Compare Globus Medical Inc. Class A Common Stock (GMED) vs Nasdaq100 ETF (QQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Nasdaq100 ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Nasdaq100 ETF trades at $721.31 (market cap $501.32B). The key difference: Nasdaq100 ETF is far larger — about 48.9× Globus Medical Inc. Class A Common Stock's market cap, and Nasdaq100 ETF is trading nearer its 52-week high, Globus Medical Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Nasdaq100 ETF for 163 Days on average.
| GMED | QQQ | |
|---|---|---|
Market Cap | $10.25B | $501.32B |
Volume | 1,108,124 | 28,524,918 |
Sector | Health | — |
52-Week High | $96.82 | $759.66 |
52-Week Low | $58.33 | $558.34 |
Typical Hold Time | 0 Days | 163 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
QQQ trades at $728.95, down 2.28% today amid broader market pressure. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators remain neutral. The ETF faces mixed analyst sentiment with a 50/50 split between buy and sell recommendations. Recent news highlights concerns about AI market sustainability and Fed rate impacts, though historical patterns suggest potential post-midterm election strength.
QQQ's concentrated tech exposure offers growth potential through AI-driven innovation but carries valuation risks amid elevated market levels. Key risks include interest rate sensitivity and sector concentration, while institutional expansion through new international ETFs signals long-term confidence in the innovation theme.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →
